echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Science: The last moment of life is still fighting in the scientific research line! Zhou Yusen et al. developed a new coronal mouse model.

    Science: The last moment of life is still fighting in the scientific research line! Zhou Yusen et al. developed a new coronal mouse model.

    • Last Update: 2020-08-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Due to the rapid increase in new cases, coviral disease (COVID-19) quickly attracted global attention in 2019, with the pathogen identified as SARS-CoV-2.
    So far (July 29), according to real-time statistics released by Johns Hopkins University, there have been more than 16.93 million confirmed cases of new pneumonia worldwide, with 660,000 deaths.
    these numbers are updated daily and are expected to increase further.
    urgently need small animal models that can sum up SARS-CoV-2 infection.
    July 31, 2020, Sun Shihui, Zhou Yusen (deceased), Qin Chengfeng and Jiang Shibo of Fudan University published a research paper entitled "Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccineac" published online in Science, which was adapted to the clinical isolation of the aging BALB/c mouse through continuous transmission.
    the lineage of adapted mice produced in the 6th generation (called MASCp6) showed increased infection in the lungs of mice and caused interstitial pneumonia and inflammatory reactions in young and elderly mice after nasal inoculation.
    deep sequencing reveals a set of adaptive mutations that may be associated with increased toxicity.
    specifically, the N501Y mutation is located in the receptor-binding domain (RBD) of the stingprotein.
    the model was used to verify the protective efficacy of recombinant RBD vaccine candidates.
    , therefore, the mouse adaptation strain and associated challenge models should be valuable in evaluating vaccines and antiviral drugs for SARS-CoV-2.
    coronary virus disease (COVID-19) quickly gained global attention in 2019 due to the rapid increase in new cases.
    new coronavirus infection is thought to be transmitted from animals and the pathogen has been identified as SARS-CoV-2.
    by January 2020, the initial infected patients are suspected to have been infected through human-to-human transmission.
    since January 2020, the virus has spread rapidly to large parts of China and other countries.
    the rapid increase in new cases, 2019 coronavirus disease (COVID-19) quickly attracted global attention, with the pathogen identified as SARS-CoV-2.
    So far (July 29), according to real-time statistics released by Johns Hopkins University, there have been more than 16.93 million confirmed cases of new pneumonia worldwide, with 660,000 deaths.
    these numbers are updated daily and are expected to increase further.
    SARS-CoV-2 belongs to the Coronavirus genus of the coronary virus family, along with two other closely related highly pathogenic virusSARS-CoV and MERS-CoV.
    the positive chain single-stranded RNA genome length of SARS-CoV-2 is 30 kb, covered by the internal nucleoshell protein (N) and an external envelope consisting of membrane (M) and envelope (E) proteins, as well as the sting (S) protein. similar to SARS-CoV
    , the S protein of SARS-CoV-2 binds to the receptor angiotensin conversion enzyme 2 (ACE2) that they share through the receptor binding domain (RBD), thus mediating the virus into the host cell.
    previously found that THE RBD of SARS-CoV and MERS-CoV contain the main conformational dependence neutralizing and epial, and can trigger effective neutralizing antibodies in immune animals, thus representing a promising target for vaccine development.
    urgently need small animal models that can sum up SARS-CoV-2 infection.
    because SARS-CoV-2 does not use mice ACE2 as its receptor, wild mice are considered to be less sensitive to SARS-CoV-2. Genetically modified mice that
    expression human ACE2 have been developed using different strategies.
    these mice have previously been used to study SARS-CoV-2 infection and pathogenesis and to evaluate responses to COVID-19.
    here, the mice reported in the study adaptto the production of SARS-CoV-2, which can be effectively replicated in the respiratory tract and cause mesoplasmic pneumonia in mice with strong wild immune ability. In addition, the protective efficacy of newly developed recombinant subunit vaccine candidates was detected using this mouse attack model.

    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.